Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTEMPO: Multiple-ascending-dose AZD9550 in overweight/obese adults with type 2 diabetes mellitus
jRCT2071240013Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- May 2024
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatohepatitis (MASH) comparing AZD9550 up-titration with Placebo (2 arms). Primary endpoints: Safety and tolerability of AZD9550 in Japanese participants (Part D), Pharmacokinetics of AZD9550 (Part D) and 1 more. Started May 2024; status: active, not recruiting.
02
Drugs
AZD9550
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on jRCT2071240013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240013.